ClearPoint Neuro (CLPT) Expected to Announce Quarterly Earnings on Thursday

ClearPoint Neuro (NASDAQ:CLPT) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $9.60 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. The company had revenue of $9.22 million during the quarter, compared to analysts’ expectations of $9.20 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Down 10.6%

CLPT stock opened at $24.11 on Thursday. The company has a market cap of $685.45 million, a P/E ratio of -29.77 and a beta of 1.19. ClearPoint Neuro has a 52 week low of $9.76 and a 52 week high of $30.10. The company’s 50-day moving average price is $18.11 and its 200 day moving average price is $14.19. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CLPT. Stifel Nicolaus lifted their price target on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Wall Street Zen raised ClearPoint Neuro from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insider Buying and Selling at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 26,463 shares of ClearPoint Neuro stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $26.98, for a total transaction of $713,971.74. Following the completion of the transaction, the chief executive officer directly owned 217,059 shares in the company, valued at $5,856,251.82. The trade was a 10.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.97% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ClearPoint Neuro

A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC increased its position in ClearPoint Neuro by 156.3% during the first quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after buying an additional 452,043 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of ClearPoint Neuro by 98.3% during the first quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after acquiring an additional 127,823 shares during the last quarter. Bank of America Corp DE increased its position in ClearPoint Neuro by 315.0% during the 2nd quarter. Bank of America Corp DE now owns 113,698 shares of the company’s stock worth $1,358,000 after purchasing an additional 86,304 shares in the last quarter. Man Group plc raised its stake in ClearPoint Neuro by 17.4% in the 2nd quarter. Man Group plc now owns 71,884 shares of the company’s stock valued at $858,000 after purchasing an additional 10,674 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in ClearPoint Neuro in the 2nd quarter valued at about $450,000. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.